Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Role of sorafenib in HCC patients with compromised liver function

Sorafenib is the standard treatment for patients with advanced hepatocellular carcinoma who are not eligible for locoregional therapy. Although significant improvement in overall survival has been demonstrated in patients with Child-Pugh A cirrhosis, information is lacking on the benefits, if any, in patients with compromised liver function and Child-Pugh B or C cirrhosis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646–649 (1973).

    Article  CAS  Google Scholar 

  2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  Google Scholar 

  3. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).

    Article  CAS  Google Scholar 

  4. Kane, R. C. et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14, 95–100 (2009).

    Article  CAS  Google Scholar 

  5. Zhu, A. X. & Clark, J. W. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy. Oncologist 14, 67–69 (2009).

    Article  Google Scholar 

  6. Abou-Alfa, G. K. et al. Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis? [abstract] ASCO Meeting Abstracts. 26, a4518 (2008).

    Google Scholar 

  7. Wörns, M. A. et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 43, 489–495 (2009).

    Article  Google Scholar 

  8. Pinter, M. et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14, 70–76 (2009).

    Article  Google Scholar 

  9. Miller, A. A. et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 27, 1800–1805 (2009).

    Article  CAS  Google Scholar 

  10. Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698–711 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Massimo Di Maio.

Ethics declarations

Competing interests

M. Di Maio, B. Daniele and F. Perrone declare that they are on the speakers bureau for Bayer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Maio, M., Daniele, B. & Perrone, F. Role of sorafenib in HCC patients with compromised liver function. Nat Rev Clin Oncol 6, 505–506 (2009). https://doi.org/10.1038/nrclinonc.2009.114

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.114

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing